pharmaphorum3d
First biosimilar fast-acting insulin reaches US market
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Pharm Exec4d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
The Financial Express6d
FDA gives nod to first rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...
Interesting Engineering on MSN3d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Managed Healthcare Executive2d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Sierra Sun Times4d
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...
조선일보4d
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.
Medscape5d
A Review of 20 Years' Experience With the Novopen Family of Insulin Injection Devices
NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Pharmabiz4d
US FDA approves Sanofi-Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes
Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes: Maryland Monday, February 17, 202 ...